NCT03258580

Brief Summary

Objective The current proposal investigates behavioral, psychophysiological, and social processes that may help explain biases and disparate outcomes in pain. Health disparities, or health outcomes that adversely affect disadvantaged populations, are pervasive and apparent in many diseases and symptoms, including pain. Pain is the number one reason individuals seek medical treatment. Health disparities in pain encompass both differences in pain experience and treatment for pain. For instance, research indicates that Black individuals report increased pain and have reduced pain tolerance relative to White individuals, yet doctors are less likely to treat minority patients pain and underestimate their pain experience. This project aims to address this systemic discrepancy by focusing on interpersonal processes that may contribute to these disparities, including socially-relevant responses to pain (i.e. pain expression) and pain assessment (e.g. visual attention). The proposed research aims to determine whether the study of pain expressions and their assessment can yield insights on how social factors shape pain and its treatment. Further, we test the efficacy of potential interventions designed to improve accuracy and reduce biases in pain assessment. If successful, this work will form the foundation of a new research program that will link the field of pain research with the field of social neuroscience, and forge new insights on the critical problem of health disparities in pain. Study population We will accrue up to 700 total healthy volunteers to target 240 completers Design Our overall aim is to understand how social factors influence the assessment and management of pain, and to gain insight into psychosocial processes that may underlie health disparities in pain. We propose a series of studies designed to test these links. First, we will measure pain perception and physiological responses to painful stimuli in a diverse group of individuals to test for sociocultural and biological influences on pain and pain-related responses. In subsequent studies, new participants ("perceivers") will view images of these initial participants ("targets") and will provide estimates of 'targets' pain experience. We will measure a) whether perceivers can accurately estimate 'targets' pain experience; b) whether accuracy differs as a function of similarity between target and perceiver (ingroup vs outgroup); and c) whether individuals can improve accuracy through feedback. Outcome measures Primary outcome measures for all experiments will be decisions about pain (experienced by self or other) measured with visual analogue scales, reaction time, and/or categorical judgments (pain/no pain). We will also measure physiological responses (e.g., facial muscle response, skin conductance, pupil dilation) and brain responses using functional magnetic resonance imaging (fMRI) as secondary outcome measures. We will test whether pain and pain-related responses varies as a function of sociocultural/demographic factors (e.g. race, ethnicity, sex) and whether accuracy in assessing others' pain is influenced by group similarity (i.e. ingroup vs. outgroup) and training (e.g. performance-related feedback)....

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
700

participants targeted

Target at P75+ for not_applicable

Timeline
13mo left

Started May 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress88%
May 2018May 2027

First Submitted

Initial submission to the registry

August 22, 2017

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 23, 2017

Completed
9 months until next milestone

Study Start

First participant enrolled

May 9, 2018

Completed
9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 17, 2027

Expected
13 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2027

Last Updated

April 24, 2026

Status Verified

December 1, 2025

Enrollment Period

9 years

First QC Date

August 22, 2017

Last Update Submit

April 23, 2026

Conditions

Keywords

PainVisual Analogue Pain ScaleHealthy VolunteerEYE TRACKINGEye Movement

Outcome Measures

Primary Outcomes (2)

  • Physiological responses (facial muscle movement, skin conductance, respiration, pupil dilation, eye gaze position)

    We measure facial responses to painful stimuli in substudy 1 and eye position in substudy 2 and 3.

    Every visit

  • Pain perception (pain ratings)

    Individuals report their perceived pain or the pain they associate with other people they are viewing.

    Every visit

Secondary Outcomes (1)

  • Questionnaire measures (e.g. Fear of Pain questionnaire, McGill pain questionnaire)

    Every visit

Study Arms (4)

Substudy 1: All participants

EXPERIMENTAL

Measuring facial response to painful stimulation.

Device: Medoc thermal stimulatorDevice: Electric shock stimulatorDevice: Cold water bath

Substudy 2: Healthy volunteers

NO INTERVENTION

Measuring pain assessment accuracy

Substudy 3: Control

NO INTERVENTION

Subjects will judge stimuli with the same instructions as Sub-Study 2 (which provides a test of replication).

Substudy 3: Feedback Group

EXPERIMENTAL

Participants in substudy 3's Feedback Group will be informed about their performance after every trial when making judgments about other people's pain.

Behavioral: Pain assessment performance feedback

Interventions

Heat pain stimulation for substudy 1

Substudy 1: All participants

Electric pain stimulation for substudy 1

Substudy 1: All participants

Cold pain stimulation for substudy 1

Substudy 1: All participants

Participants in substudy 3's Feedback Group will be informed about their performance after every trial when making judgments about other people's pain.

Substudy 3: Feedback Group

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • All Sub-Studies:
  • Healthy
  • Between 18 and 60 years old
  • Fluent in English
  • Able to provide written informed consent

You may not qualify if:

  • All Sub-Studies:
  • Unable to comply with study procedures
  • Has a major-medical condition or medical history that in a clinician's assessment could affect ability to comply with study procedures, including neurological conditions (including stroke, blindness or deafness, or a history of brain damage)
  • Has a current mood disorder, anxiety disorder, or substance use disorder, or has a history of psychosis, hospitalization for a mental health condition, or recurrent psychiatric episodes.
  • NIH staff member who is a subordinate/relative/co-worker of any investigator on the protocol
  • Prior completion of a different sub-study within this protocol.
  • Is born outside of the states or territories of the United States of America
  • Does not currently reside in a state or territory of the United States of America
  • Sub-study 1:
  • Has a major-medical condition or medical history that in a clinician's assessment could affect heat sensitivity or pain thresholds. This may include cardiovascular, autonomic, or neurological conditions or a chronic systemic disease (e.g., diabetes)
  • Has a medical condition that in a clinician's assessment might affect somatosensation (e.g., Raynaud's disease, peripheral neuropathy, or circulatory disorder)
  • Has a current chronic pain condition or has had chronic pain in the past (painful condition lasting more than six months)
  • Has a dermatological condition affecting the testing region, such as scars, burns, or recent tattoos that might influence cutaneous sensibility
  • Regular use of prescription medication that has a significant effect on pain or heat perception. Excluded medications include central-acting agents such as opiates (morphine, tramadol), antidepressants (amitriptyline, duloxetine, milnacipran), anticonvulsants (gabapentin, pregabalin), anxiolytics (barbituates, benzodiazepines), hypnotics (zolpidem, sodium oxybate), antipsychotics (valproate, lithium, olanzapine), antimigraine agents (sumatriptan, ergotamine), and muscle relaxants (cyclobenzaprine, carisoprodol). Use of analgesic medications, such as non-steroidal anti-inflammatories, salicylates, and acetaminophen, taken on an "as needed" basis is acceptable as long as the last dose was not taken was within 5 half-lives of testing.
  • Is left handed
  • +10 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Pain

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Lauren Y Atlas, Ph.D.

    National Center for Complementary and Integrative Health (NCCIH)

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Adebisi O Ayodele, C.R.N.P.

CONTACT

Lauren Y Atlas, Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SEQUENTIAL
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 22, 2017

First Posted

August 23, 2017

Study Start

May 9, 2018

Primary Completion (Estimated)

May 17, 2027

Study Completion (Estimated)

May 30, 2027

Last Updated

April 24, 2026

Record last verified: 2025-12-01

Data Sharing

IPD Sharing
Will share

Deidentified data will be shared with other researchers as per the protocol. Identifiable data (i.e. images of faces) from participants who consent to data sharing may be shared with other researchers. Finally, identifiable data from participants who opt to be included in a stimulus set through the sub-study 1 consent form can be shown to other participants and in other studies to measure evaluation of facial responses to pain.

Shared Documents
ICF, CSR, ANALYTIC CODE
Time Frame
Face stimuli are available following completion for viewing by other study participants. Deidentified data will be made available upon publication.
Access Criteria
please see above.

Locations